Clinical Trials

30 enrolled

Pancreatic Neoplasms

NCT06378840 2024-04-23

the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer

Unknown

20 enrolled

Gynecologic

Locally Advanced Cervical Carcinoma

NCT04447092 2024-04-19

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

77 enrolled

Pancreatic Neoplasms

NCT05064618 2024-04-04

MIKE-1

55 enrolled

Pancreatic Neoplasms

NCT04537286 2024-02-26

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

90 enrolled

Breast Neoplasms

NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

30 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06169410 2024-01-23

Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric Cancer

Phase 4 Unknown

140 enrolled

Advanced Gastric Cancer

NCT04395989 2023-12-22

FUTURE-SUPER

139 enrolled

Triple Negative Breast Neoplasms

NCT04734262 2023-11-18

SPARK

98 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05174832 2023-09-28

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

136 enrolled

Triple Negative Breast Neoplasms

NCT03777462 2023-09-01

BRPCNCC-1

150 enrolled

Pancreatic Neoplasms

NCT04324307 2023-09-01

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

60 enrolled

Pancreatic Neoplasms

NCT05816694 2023-04-18

The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train.

50 enrolled

Thymoma

NCT05633914 2023-02-21

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

90 enrolled

HR+/HER2- Breast Cancer

NCT05640791 2022-12-07

Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

40 enrolled

Resectable Biliary Tract Cancer

NCT03907800 2022-10-27

NeoPATH

100 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03487016 2022-09-08

FOOTPATH

270 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT03805399 2022-08-10

FUTURE

140 enrolled

Triple Negative Breast Neoplasms

NCT05491694 2022-08-08

HIFU

20 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05441254 2022-07-08

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

33 enrolled

Stage IV Gastric Cancer With Metastasis

NCT05444998 2022-07-06

Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer

20 enrolled

Breast Neoplasms

NCT04876313 2022-04-06

NURE-Combo

29 enrolled

Muscle-Invasive Bladder Carcinoma

NCT05178628 2022-03-29

imPaCT-PRO

Phase 3 Unknown

450 enrolled

Pancreatic Neoplasms, Thromboembolism

NCT04995120 2022-01-18

INSIGHT

42 enrolled

Head & Neck

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT04129996 2022-01-11

A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)

46 enrolled

Triple Negative Breast Neoplasms

NCT05185869 2022-01-11

SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer

58 enrolled

Pancreatic Neoplasms

NCT05070598 2021-10-07

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

35 enrolled

HER2-positive Gastric Cancer

NCT04979585 2021-08-03

Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma

66 enrolled

Dermatologic

Melanoma

NCT04541251 2021-06-23

Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04907344 2021-05-28

Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 2/3 Unknown

420 enrolled

Triple Negative Breast Neoplasms

NCT04814485 2021-05-25

Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

39 enrolled

Pancreatic Neoplasms

NCT04900311 2021-05-25

Pyramid

490 enrolled

HER2+ Early or Locally Advanced Breast Cancer

NCT04725448 2021-04-06

Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma

27 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Thoracic Neoplasms

NCT04826679 2021-04-01

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

53 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04563975 2021-03-17

Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer

54 enrolled

Stomach Neoplasms

NCT04692051 2020-12-31

A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer

100 enrolled

Biliary Tract Neoplasms

NCT03989310 2020-12-23

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

50 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04659499 2020-12-09

Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast Cancer

261 enrolled

Breast Neoplasms

NCT04530227 2020-11-13

Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC

30 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT04554524 2020-10-28

Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma

Phase 4 Unknown

40 enrolled

Thymoma

NCT04581876 2020-10-09

The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic Cancer

120 enrolled

Pancreatic Neoplasms

NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

46 enrolled

Locally Advanced or Metastatic Gastric Adenocarcinoma

NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

50 enrolled

Borderline Resectable Pancreatic Cancer

NCT03943043 2020-07-29

Gemcitabine + Oxaliplatin +Nab-paclitaxel in Subjects With Advanced Biliary Tract Cancer

85 enrolled

Cholangiocarcinoma

NCT04216758 2020-06-30

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

300 enrolled

Stage IA Pancreatic Adenocarcinoma

NCT04017377 2020-04-28

VMAT Concurrent Cisplatin Plus Nab-paclitaxel for Local Advanced Cervical Cancer

Phase NA Unknown

15 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

60 enrolled

Borderline Resectable Pancreatic Cancer

NCT03885219 2020-03-10

Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

60 enrolled

Locally Advanced Pancreatic Cancer

NCT04213937 2019-12-30

Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

386 enrolled

Extensive Stage Small Cell Lung Cancer

NCT04182724 2019-12-03

Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

57 enrolled